Literature DB >> 21801776

Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.

S Elizabeth Williams1, Nicola P Klein, Neal Halsey, Cornelia L Dekker, Roger P Baxter, Colin D Marchant, Philip S LaRussa, Robert C Sparks, Jerome I Tokars, Barbara A Pahud, Laurie Aukes, Kathleen Jakob, Silvia Coronel, Howard Choi, Barbara A Slade, Kathryn M Edwards.   

Abstract

BACKGROUND: In 2004 the Clinical Consult Case Review (CCCR) working group was formed within the CDC-funded Clinical Immunization Safety Assessment (CISA) Network to review individual cases of adverse events following immunizations (AEFI).
METHODS: Cases were referred by practitioners, health departments, or CDC employees. Vaccine Adverse Event Reporting System (VAERS) searches and literature reviews for similar cases were performed prior to review. After CCCR discussion, AEFI were assessed for a causal relationship with vaccination and recommendations regarding future immunizations were relayed back to the referring physicians. In 2010, surveys were sent to referring physicians to determine the utility and effectiveness of the CCCR service.
RESULTS: CISA investigators reviewed 76 cases during 68 conference calls between April 2004 and December 2009. Almost half of the cases (35/76) were neurological in nature. Similar AEFI for the specific vaccines received were discovered for 63 cases through VAERS searches and for 38 cases through PubMed searches. Causality assessment using the modified WHO criteria resulted in classifying 3 cases as definitely related to vaccine administration, 12 as probably related, 16 as possibly related, 18 as unlikely related, 10 as unrelated, and 17 had insufficient information to assign causality. The physician satisfaction survey was returned by 30 (57.7%) of those surveyed and a majority of respondents (93.3%) felt that the CCCR service was useful.
CONCLUSIONS: The CCCR provides advice about AEFI to practitioners, assigns potential causality, and contributes to an improved understanding of adverse health events following immunizations.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801776      PMCID: PMC5832019          DOI: 10.1016/j.vaccine.2011.07.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  50 in total

1.  Withdrawal of rotavirus vaccine recommendation.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-11-05       Impact factor: 17.586

2.  Reactogenicity profile of tetanus-diphtheria (adult-type) vaccine: results of a naturalistic study performed at an adult vaccination center.

Authors:  A Vilella; R Dal-Ré; D Simó; P García-Corbeira; P Diego; J M Bayas
Journal:  J Clin Pharmacol       Date:  2000-11       Impact factor: 3.126

3.  Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-06-11       Impact factor: 17.586

Review 4.  A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.

Authors:  Paolo Bonanni; Catherine Cohet; Susanne K Kjaer; Nina B Latham; Paul-Henri Lambert; Keith Reisinger; Richard M Haupt
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

5.  Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Authors:  Katrin S Kohl; Leslie Ball; Jane Gidudu; Sandra Jo Hammer; Scott Halperin; Paul Heath; Renald Hennig; Jerry Labadie; Edward Rothstein; Anne Schuind; Frederick Varricchio; Wikke Walop
Journal:  Vaccine       Date:  2007-05-11       Impact factor: 3.641

6.  Intussusception among infants given an oral rotavirus vaccine.

Authors:  T V Murphy; P M Gargiullo; M S Massoudi; D B Nelson; A O Jumaan; C A Okoro; L R Zanardi; S Setia; E Fair; C W LeBaron; M Wharton; J R Livengood; J R Livingood
Journal:  N Engl J Med       Date:  2001-02-22       Impact factor: 91.245

7.  Viscerotropic disease following yellow fever vaccination in Peru.

Authors:  Alvaro Whittembury; Gladys Ramirez; Herminio Hernández; Alba Maria Ropero; Steve Waterman; María Ticona; Margo Brinton; Jorge Uchuya; Mark Gershman; Washington Toledo; Erin Staples; Clarense Campos; Mario Martínez; Gwong-Jen J Chang; Cesar Cabezas; Robert Lanciotti; Sherif Zaki; Joel M Montgomery; Thomas Monath; Edward Hayes
Journal:  Vaccine       Date:  2009-08-11       Impact factor: 3.641

8.  The Elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal.

Authors:  Moussa Fafa Cissé; J Gabrielle Breugelmans; Mamadou Bâ; Mouhamed Boss Diop; Papa Coumba Faye; Bekithemba Mhlanga; Judith E Mueller; David Koffi; Bradford D Gessner
Journal:  Pediatr Infect Dis J       Date:  2010-06       Impact factor: 2.129

9.  Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.

Authors:  L B Schonberger; D J Bregman; J Z Sullivan-Bolyai; R A Keenlyside; D W Ziegler; H F Retailliau; D L Eddins; J A Bryan
Journal:  Am J Epidemiol       Date:  1979-08       Impact factor: 4.897

10.  Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.

Authors:  Jon L Belsher; Peter Gay; Margo Brinton; Joseph DellaValla; Robert Ridenour; Robert Lanciotti; Andrey Perelygin; Sherif Zaki; Christopher Paddock; Troy Querec; Tuofu Zhu; Bali Pulendran; Rachel B Eidex; Edward Hayes
Journal:  Vaccine       Date:  2007-09-18       Impact factor: 3.641

View more
  7 in total

1.  Vaccine safety: An evolving evidence-based science.

Authors:  Bruce M McClenathan; Kathryn M Edwards
Journal:  Br J Clin Pharmacol       Date:  2019-08-19       Impact factor: 4.335

2.  Authors' reply: Safety of Human Papillomavirus Vaccines.

Authors:  Kristine Macartney; Anastasia Phillips; Cyra Patel; Alexis Pillsbury; Julia Brotherton
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

Review 3.  Immune-mediated adverse reactions to vaccines.

Authors:  Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2019-11-05       Impact factor: 4.335

4.  Canadian paediatricians' approaches to managing patients with adverse events following immunization: The role of the Special Immunization Clinic network.

Authors:  Karina A Top; Joseline Zafack; Gaston De Serres; Scott A Halperin
Journal:  Paediatr Child Health       Date:  2014-06       Impact factor: 2.253

5.  Vaccine-Associated Anaphylaxis.

Authors:  Michael M McNeil
Journal:  Curr Treat Options Allergy       Date:  2019-07-16

6.  Surveillance and compensation claims for adverse events following immunization from 2011 to 2016 in the Republic of Korea.

Authors:  Min-Kyung Kim; Yeon Kyeong Lee; Tae Eun Kim; Insik Kong; Hyeon-Jong Yang; Eun Sook Suh
Journal:  Clin Exp Vaccine Res       Date:  2017-07-26

7.  Comprehensive assessment of serious adverse events following immunization by health care providers.

Authors:  S Elizabeth Williams; Kathryn M Edwards; Roger P Baxter; Philip S LaRussa; Neal A Halsey; Cornelia L Dekker; Claudia Vellozzi; Colin D Marchant; Peter D Donofrio; Tyler E Reimschisel; Melvin Berger; Jane F Gidudu; Nicola P Klein
Journal:  J Pediatr       Date:  2013-02-26       Impact factor: 4.406

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.